Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: SAD Placebo 100mg Clear all

Conditions: Obese, Overweight, Healthy
Interventions: LB64640, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions: TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: SAD IMG-004 30mg, SAD IMG-004 100mg, SAD IMG-004 200mg, SAD IMG-004 400mg, SAD IMG-004 600mg, SAD Placebo 30mg, SAD Placebo 100mg, SAD Placebo 200mg, SAD Placebo 400mg, SAD Placebo 600mg, MAD IMG-004 50mg, MAD Placebo 50mg, MAD IMG-004 150mg, MAD Placebo 150mg, MAD IMG-004 300mg, MAD Placebo 300mg, FE IMG-004 150mg; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: COPD, Anxiety, Depression, Stress, Interstitial Lung Disease
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses, Placebo multiple ascending doses; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo; Drug
Lead sponsor: Curacle Co., Ltd.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: AZD4205, Placebo; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Influenza
Interventions: Placebo for VNT-101, VNT-101; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimer Disease
Interventions: ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD; Drug
Lead sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: NIP292 tablet, NIP292 tablets; Drug
Lead sponsor: The National Institutes of Pharmaceutical R&D Co. Ltd, China; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Heart Failure
Interventions: THRV-1268, Placebo; Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: PF-06260414, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Social Anxiety Disorder
Interventions: Pristiq, Placebo; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Study to Evaluate IMG-004 in Healthy Participants

Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

A Study of AZD4205 in Healthy Adult Subjects

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder